News
Glox Therapeutics awarded £1m PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant...
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, has secured £1 million in grant funding from...
UCB receives U.S. FDA approval for BIMZELX as first IL-17A and IL-17F inhibitor for...
The U.S. Food and Drug Administration (FDA) has approved UCB's BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa (HS)....
Cytomos secures £5m to scale up production of cell analysis technology
Cytomos, an Edinburgh-based biotechnology company, has raised £5 million to scale up production of its unique cell analysis technology.
The oversubscribed funding round was led...
